A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

Khyatiben Rana,1 Jessica Reid,1 Joshua N Rosenwasser,2 Todd Lewis,3 Mae Sheikh-Ali,4 Rushab R Choksi,1 Rebecca F Goldfaden1 1East Coast Institute for Research, Jacksonville, FL, USA; 2Lincoln Medical and Mental Health Center, Bronx, NY, USA; 3Baker-Gilmour Cardiovascular Institute, Jacksonville, FL,...

Full description

Bibliographic Details
Main Authors: Rana K, Reid J, Rosenwasser JN, Lewis T, Sheikh-Ali M, Choksi RR, Goldfaden RF
Format: Article
Language:English
Published: Dove Medical Press 2019-09-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
Praluent
Alirocumab
PCSK9
PCSK9-inhibitor
Cardiovascular Disease
Atherosclerosis
Dyslipidemia
Online Access:https://www.dovepress.com/a-spotlight-on-alirocumab-in-high-cardiovascular-risk-patients-with-ty-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/a-spotlight-on-alirocumab-in-high-cardiovascular-risk-patients-with-ty-peer-reviewed-article-DMSO

Similar Items